INTRODUCTION
Proton pump inhibitors (PPIs) are the most powerful agent of suppressing gastric acid secretion and function by inhibiting H+,K+-ATPase (proton pump) of the stomach. These medications reduce the production of stomach acid from 80% to 90%. PPIs are intended for the treatment of gastric and duodenal ulcers and to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome (ZES), and as a component in a related treatment of Helicobacter pylori (H. pylori) infection 1 PPIs became known in 1989 for the treatment of peptic ulcer disease. Omeprazole is a common drug which until recently, was one of the most widely prescribed drugs worldwide. Following the release of omeprazole in the market, other types of PPIs were launched-lansoprazole (1995), pantoprazole (1997), rabeprazole (1999), and esomeprazole (2001). 2 A study showed that PPI drugs are some of the most widely prescribed drugs worldwide in both primary treatment and secondary treatment; yet, approximately 25-70% of patients taking this drug do so without proper indication. 3 The guidelines of the National Institute of Clinical Excellence (NICE) on PPI therapy recommend regular monitoring of patients receiving PPI therapy to assess their need for the drug and maintenance therapy with lower doses or other alternative medicines to control symptoms. 4 The percentage of gastrointestinal side effects of PPI such as diarrhoea and constipation are 3-4% and 1-2%, respectively. 5 Reduction of acid production due to the use of PPIs can cause microorganisms to colonize in the upper gastrointestinal tract. Enteric infection is often associated with Clostridium difficile (C.difficile), which causes gastroenteritis and even death. 6 PPI use with C. difficile is associated with diarrhoea. Diarrhoea is the most common side effect reported from the long-term use of PPI medications. The range of diarrhoea incidence reported is from 3.7% to 4.1%. 7 Another study states that the rate of side effects of constipation due to the use of PPIs is at 10%. 8 Gastrointestinal diseases can have an effect on the quality of life of patients as well as their healthcare utilization. Results of another study stated that the percentage of gastrointestinal complaints amounted to 61.7%, 14.9% of which were due to constipation. 9 Therefore, it is important to monitor drug side effects. The purpose of this study was to prospectively analyse gastrointestinal side effects of PPIs used by inpatients of Gatot Subroto Hospital.
METHODS

Study Design
This is a descriptive analytic study; data were collected prospectively from prescriptions and patient medical records, and primary data obtained through interviews using a valid and reliable questionnaire. The population in this study comprises the data of all inpatient of the Department of Internal Medicine at Gatot Soebroto Hospital from February to April 2016. The sample was the data of all inpatients in the Department of Internal Medicine at Gatot Soebroto Hospital from February to April 2016 who met the inclusion criteria. Inclusion criteria in this study are the data of patient's ≥17 years old who received PPI and were willing to participate in the study by signing the informed consent. Exclusion criteria are the data of patients who left before treatment was completed, patients who experienced diarrhoea or constipation prior to being hospitalized, and prescriptions or medical records that were unclear or could not be read. Patients with dropout criteria are patients who could not be monitored and those who died during treatment. The history of PPI use was obtained from medical records or patient interviews.
RESULTS
The total number of patients who received PPIs when hospitalized in the Department of Internal Medicine at Gatot Soebroto Hospital from February to April 2016 are 91 patients. A total of 25 patients were included in the exclusion criteria, of which 19 had diarrhoea and 6 experienced constipation before entering the hospital. Four patients were not willing to be the subject of research. A total of 62 patients were part of the inclusion criteria. Four patients were excluded as subjects of research (drop out) due to death during hospitalization; thus, the total number subjects of research were 58 patients.
Patient Characteristics
The age range of patients in this study is 20-81 years old. Majority of the research subjects were female (58.6%), and many of them within an age range of 46-55 years old (41.4%). The most primary diagnosis from the subject of this study are patients with DHF (Dengue High Fever) as many as 15 patients (25.9%). Seven patients (12.1%) with dyspepsia, and one patient (1.7%) with stroke. In all, 15 patients (25.9%) had received PPIs prior to being hospitalized, 11 patients (18.9%) never received PPIs prior to being hospitalized, and 32 patients (55.2%) had an unknown history of PPI use (Table 1.) In this study, all of the subjects were given omeprazole with the total 110 therapies. Omeprazole with a dose regimen of 2 x 20 mg and 1 x 40 mg are the most widely used with the percentage 39.10% and 37.27% respectively. Omeprazole therapy with 2 x 20 mg dose regimen that use fewer than two weeks is the most widely used (37, 28%), while 1 x 40 mg dose regimen is 34.55%. Total of oral route administration were 52 therapies (47.28%), and intravenous routes were 58 therapies (52.72%).
Gastrointestinal Side Effect
From the secondary data, such as prescriptions and medical records, as well as primary data from patient interviews, 19 patients experienced constipation. The side effect of diarrhoea was not found in the subjects. On the basis of analysis from the Naranjo algorithm, it was found that 16 patients (27.58%) were in the probable category and 3 patients (5.17%) were in the possible category for experiencing gastrointestinal side effects such as constipation. The chi-square test with significance value (two-sided) showed no association between gender, age, PPI dose, and duration of PPI administration with gastrointestinal side effects.
DISCUSSION
This result was contrary to study at a Hospital in India in 2015 [11] , majority of this research subjects were female (58.6%), and many of them within an age range of 46-55 years old (41.4%). Where as at Hospital in India, most of PPI were prescribed for male (56%) with a mean age group of 50-60 years (26%).
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The percentage of patients who suffer from constipation in this study was quite high compare to other studies 9, 12, 13 After 8 weeks of PPI treatment, 2% of patients complained of diarrhoea, while after 6 months of treatment, 17% patients experienced diarrhoea and 2% reported constipation. 9 The percentage of gastrointestinal side effects due to PPI therapy according to the American Pharmacist Association was 2% with constipation and 3-4% with diarrhea. 5 A study from McCrea et al. (2009) showed that the prevalence of constipation in women is higher than in men. 13 The percentage of the elderly age group category in this study who experienced side effects was higher (37.5%) than the adult age group (32%). In this study, there were no reported gastrointestinal side effects such as diarrhoea; this may be due to the duration of PPI use having been less than 2 weeks. Another study showed that 19 of the 489 patients who received PPIs for more than 30 days or >4 weeks complained of side effects such as C. difficile-associated diarrhoea. 
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